Scientific Advisory Board

Kazuyuki Yoshikazi



Kazuyuki Yoshikazi, MD, PhD, is a Professor in the Dept of Immuno-Medical Science at Osaka University, Japan. He was the principal investigator that identified IL-6 as the key cytokine in the pathogenesis of MCD (1989), found anti-IL-6R Ab improved the abnormal findings of MCD (2002), and found the mechanism of inflammatory anemia via IL-6 induced hepcidin (2010). The anti-IL-6R antibody that Dr Yoshizaki developed (now called tocilizumab) was first approved for MCD in Japan and was then repurposed for rheumatoid arthritis (RA), severe COVID-19, Adult onset Still’s disease, Juvenile idiopathic arthritis, Juvenile RA, cytokine storm following CAR-T cell therapy, Giant cell Arteritis, Takayasu Arteritis, Neuro-myelitis-Optical (NMO), and beyond. Tocilizumab is one of the most widely repurposed drugs of all time and serves as an inspirational example for Every Cure and our leadership team.

Arrow Shape Facebook Instagram Twitter Youtube Play Arrow Left